Physician profile
Ronald Leo
NPI 1295700623
$9,122.23
in general payments reported to CMS, 2019-2025
38 companies · $1,397 in 2025
The $1,397 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,160 · 2020: $1,999 · 2021: $576 · 2022: $864 · 2023: $998 · 2024: $1,129 · 2025: $1,397.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,524.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,523.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,301.19 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $1,768.44 | 2019-2025 | |
| Celgene Corporation | $504.65 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $483.39 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $431.11 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $362.90 | 2022-2025 | |
| Ardelyx, INC. | $339.62 | 2022-2025 | Ibsrela |
| Pfizer INC. | $313.77 | 2019-2025 | |
| Gilead Sciences, INC. | $154.91 | 2021-2025 | |
| Madrigal Pharmaceuticals | $122.73 | 2024-2025 | Resmetirom, Rezdiffra |
| Ipsen Biopharmaceuticals, INC | $112.66 | 2025 | Iqirvo |
| Ferring Pharmaceuticals INC. | $112.47 | 2019-2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $94.63 | 2024-2025 | Dupixent |
| Boston Scientific Corporation | $93.22 | 2022-2024 | Orca |
| Redhill Biopharma INC. | $90.51 | 2021-2023 | Talicia |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $84.34 | 2020-2022 | |
| Mallinckrodt Hospital Products INC. | $82.34 | 2022-2023 | Terlivaz |
| Mirum Pharmaceuticals, INC. | $71.52 | 2025 | Livmarli |
| Celltrion USA INC. | $65.94 | 2024-2025 | Vegzelma |
| Apollo Endosurgery US INC | $60.36 | 2019 | |
| Intercept Pharmaceuticals, INC. | $55.37 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $51.83 | 2023-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $46.82 | 2021-2024 | |
| Pharmacosmos Therapeutics INC. | $37.88 | 2021-2023 | Monoferric |
| Allergan, INC. | $33.92 | 2019 | |
| Ucb, INC. | $32.35 | 2019 | |
| Fresenius Kabi USA, LLC | $30.78 | 2023 | Idacio |
| Qol Medical, LLC | $28.34 | 2025 | Sucraid |
| Merck Sharp & Dohme LLC | $27.52 | 2022-2023 | Dificid |
| Lilly USA, LLC | $26.95 | 2025 | Omvoh |
| Aimmune Therapeutics, INC. | $18.97 | 2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $18.69 | 2021 | |
| Amgen INC. | $16.80 | 2022 | |
| Braintree Laboratories, INC. | $15.63 | 2020 | |
| Medtronic, INC. | $15.20 | 2023 | Pillcam |
| Cumberland Pharmaceuticals, INC. | $14.48 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$56,121.38 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Leo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.